Pfizer Accupril “Branded Generic” Plans Challenged By Teva

Pfizer should be required to obtain a supplemental NDA approval for Accupril before marketing a "branded generic" version of the ACE inhibitor, Teva told FDA in a June 9 1citizen petition

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet